Showing results (201-210 of 274) with videos related to
Sort By:
Pageof 28
European Journal of Cancer (Oxford, England : 1990)|August 20, 2013
A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)Gary Middleton, Sarah Brown, Catherine Lowe, et al.Cancers|October 20, 2020
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF TrialIan Chau, Nicolas Penel, Andres O Soriano, et al.British Journal of Cancer|April 21, 2026
Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trialAnderley Gordon, Amina Tran, Caroline Fong, et al.The Lancet. Oncology|December 17, 2013
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo E R Ford, Andrea Marshall, John A Bridgewater, et al.JCO Precision Oncology|September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET StudyVivek Subbiah, Radj Gervais, Gregory Riely, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 28, 2024
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trialYoon-Koo Kang, Min-Hee Ryu, Maria Di Bartolomeo, et al.Journal of Clinical Medicine|January 13, 2021
The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome SequencingIrene Y Chong, Naureen Starling, Alistair Rust, et al.Journal for Immunotherapy of Cancer|November 19, 2019
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatmentAlice Newey, Beatrice Griffiths, Justine Michaux, et al.Oncotarget|January 8, 2019
Genomic loss of heterozygosity and survival in the REAL3 trialElizabeth C Smyth, Catherine Cafferkey, Andrea Loehr, et al.The Lancet. Oncology|June 4, 2013
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trialMatthew T Seymour, Sarah R Brown, Gary Middleton, et al.Pageof 28